# A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis

> **NCT05083182** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Janssen Research & Development, LLC** · enrollment: 50 (actual)

## Conditions studied

- Arthritis, Juvenile

## Interventions

- **DRUG:** Ustekinumab
- **DRUG:** Guselkumab

## Key facts

- **NCT ID:** NCT05083182
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-08-30
- **Primary completion:** 2026-01-12
- **Final completion:** 2026-12-05
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05083182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05083182, "A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT05083182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*